Skip to main
VOR

Vor Biopharma (VOR) Stock Forecast & Price Target

Vor Biopharma (VOR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vor Biopharma has strategically enhanced its asset, financial, and management frameworks to position itself for potential commercialization within 24-30 months. The company is expected to benefit from favorable efficacy and safety profiles of its therapies, which may drive adoption rates relative to competitors, particularly in treatment for various hematological malignancies. Moreover, promising clinical trial outcomes indicate significant improvements in key health measures, suggesting strong potential for expansion opportunities and increased market penetration.

Bears say

Vor Biopharma Inc's stock outlook has been negatively impacted by a significant decrease in its price target, which has been revised down from $55 to $32 per diluted share due to share dilution associated with a recent capital raise. The disappointing offer price of $10.00 represents a substantial ~47% discount to the previous closing price of $18.80, indicating a lack of confidence in the stock's current valuation. Furthermore, challenges related to the ongoing clinical landscape, including unattractive enrollment conditions for complement inhibitors and potential risks associated with therapy, contribute to the overall pessimism surrounding the company's financial future.

Vor Biopharma (VOR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vor Biopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vor Biopharma (VOR) Forecast

Analysts have given Vor Biopharma (VOR) a Buy based on their latest research and market trends.

According to 8 analysts, Vor Biopharma (VOR) has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vor Biopharma (VOR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.